[an error occurred while processing this directive]|[an error occurred while processing this directive]
EGFR突变状态对NSCLC脑转移和放疗及靶向治疗疗效影响
曹建忠, 李红卫
030013 太原,山西省肿瘤医院(研究所) 山西医科大学附属肿瘤医院 山西省放疗中心
The effect of brain metastases from NSCLC and treatment targeted plus radiotherapy on EGFR mutations
Cao Jianzhong,Li Hongwei
Department of Radiation Oncology,Tumor Hospital(Institute) of Shanxi Province,Affilated Tumor Hospital of Sahnxi Medical University,Radiotherapy Center of Shanxi Province,Taiyuan 030013,China
Abstract： Brain metastases (BM) are one of the main cause of death in patients with non small cell lung cancer (NSCLC).The prognosis is still poor,despite standard therapy based on surgery and radiotherapy. In recent years,with the deepening understanding of molecular mechanisms in lung cancer,epidermal growth factor receptor (EGFR) mutation might be considered as an effective therapeutic target for NSCLC with BM.Therefore,we review the current knowledge about the correlation between EGFR mutation with prevalence and prognosis in BM.
Cao Jianzhong,Li Hongwei. The effect of brain metastases from NSCLC and treatment targeted plus radiotherapy on EGFR mutations[J]. Chinese Journal of Radiation Oncology, 2016, 25(3): 296-299.
[1] Siegel RL,Miller KD,Jemal A.Cancer statistics,2015[J].CA:Cancer J Clin,2015,65(1):5-29.DOI:10.3322/caac.21254. [2] On NH,Mitchell R,Savant SD,et al. Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model[J].J Neurooncol,2013,111(2):133-143.DOI:10.1007/s11060-012-1006-1. [3] Shaw MG,Ball DL.Treatment of brain metastases in lung cancer:strategies to avoid/reduce late complications of whole brain radiation therapy[J].Curr Treat Options Oncol,2013,14(4):553-67.DOI:10.1007/s11864-013-0258-0. [4] Ebert BL,Niemierko E,Shaffer K,et al. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer[J].Oncologist,2003,8(1):69-75.DOI:10.1634/theoncologist.8-1-69. [5] Mekhail T,Sombeck M,Sollaccio R.Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases:results of the EORTC 22952-26001 study[J].Curr Oncol Rep,2011,13(4):255-258.DOI:10.1007/s11912-011-0180-1. [6] Hendriks LE,Smit EF,Vosse BA,et al. EGFR mutated non-small cell lung cancer patients:more prone to development of bone and brain metastases?[J].Lung Cancer,2014,84(1):86-91.DOI:10.1016/j.lungcan.2014.01.006. [7] Heon S,Yeap BY,Lindeman NI,et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations[J].Clin Cancer Res,2012,18(16):4406-4414.DOI:10.1158/1078-0432.CCR-12-0357. [8] Stanic K,Zwitter M,Hitij NT,et al. Brain metastases in lung adenocarcinoma:impact of EGFR mutation status on incidence and survival[J].Radiol Oncol,2014,48(2):173-183.DOI:10.2478/raon-2014-0016. [9] Iuchi T,Shingyoji M,Itakura M,et al. Frequency of brain metastases in non-small cell lung cancer,and their association with epidermal growth factor receptor mutations[J].Int J Clin Oncol,2015,20(4):674-679.DOI:10.1007/s10147-014-0760-9. [10] Li Z,Lu J,Zhao Y,et al. The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis[J].J Clin Oncol,2011,29(15 Suppl):e18065. [11] Shin DY,Na II,Kim CH,et al. EGFR mutation and brain metastasis in pulmonary adenocarcinomas[J].J Thorac Oncol,2014,9(2):195-199.DOI:10.1158/1078-0432.CCR-10-1588. [12] Heon S,Yeap BY,Britt GJ,et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib[J].Clin Cancer Res,2010,16(23):5873-82.DOI:10.1158/1078-0432.CCR-10-1588. [13] Eichler AF,Kahle KT,Wang DL,et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer[J].Neuro Oncol,2010,12(11):1193-1199.DOI:10.1093/neuonc/noq076. [14] Enomoto Y,Takada K,Hagiwara E,et al. Distinct features of distant metastasis and lymph node stage in lung adenocarcinoma patients with epidermal growth factor receptor gene mutations[J].Respir Investig,2013,51(3):153-157.DOI:10.1016/j.resinv.2013.02.004. [15] Lee YJ,Park IK,Park MS,et al. Activating mutations within the EGFR kinase domain:a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma[J].J Cancer Res Clin Oncol,2009,135(12):1647-1654.DOI:10.1007/s00432-009-0611-7. [16] Sekine A,Kato T,Hagiwara E,et al. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations:distinguishing influence of exon 19 deletion on radiographic features[J].Lung Cancer,2012,77(1):64-69.DOI:10.1016/j.lungcan.2011.12.017. [17] Zheng Z,Bepler G,Cantor A,et al. Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer[J].Chest,2005,128(1):308-316.DOI:10.1378/chest.128.1.308. [18] Kaal EC,Nil CG,Vecht CJ.Therapeutic management of brain metastasis[J].Lancet Neurol,2005,4(5):289-298.DOI:10.1016/S1474-4422(05)70072-7. [19] Gaspar L,Scott C,Rotman M,et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials[J].Int J Radiat Oncol Biol Phys,1997,37(4):745-751.DOI:10.1016/S0360-3016(96)00619-0. [20] Sperduto PW,Berkey B,Gaspar LE,et al. A new prognostic index and comparison to three other indices for patients with brain metastases:an analysis of 1,960 patients in the RTOG database[J].Int J Radiat Oncol Biol Phys,2008,70(2):510-514.DOI:10.1016/j.ijrobp.2007.06.074. [21] Sperduto PW,Kased N,Roberge D,et al. Summary report on the graded prognostic assessment:an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases[J].J Clin Oncol,2012,30(4):419-425.DOI:10.1200/JCO.2011.38.0527. [22] Gow CH,Chien CR,Chang YL,et al. Radiotherapy in lung adenocarcinoma with brain metastases:effects of activating epidermal growth factor receptor mutations on clinical response[J].Clin Cancer Res,2008,14(1):162-168.DOI:10.1158/1078-0432.CCR-07-1468. [23] Lee DW,Shin DY,Kim JW,et al. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis:integrating with lung specific GPA score[J].Lung Cancer,2014,86(3):363-368.DOI:10.1016/j.lungcan.2014.10.001. [24] Lee HL,Chung TS,Ting LL,et al. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases[J].Radiat Oncol,2012,7:181.DOI:10.1186/1748-717X-7-181. [25] Hsiao SH,Lin HC,Chou YT,et al. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients[J].Lung Cancer,2013,81(3):455-461.DOI:10.1016/j.lungcan.2013.06.004. [26] 蒋涛,周彩存.非小细胞肺癌脑转移靶向治疗研究进展[J].中国肺癌杂志,2014,17(11),824-828.DOI:10.3779/j.issn.1009-3419.2014.11.09. Jiang T, Zhou CC.Research progress of targeted therapy for non-small cell lung cancer patients with brain metastases[J].Chin J Lung Cancer,2014,17(11),824-828.DOI:10.3779/j.issn.1009-3419.2014.11.09. [27] Porta R,Sánchez-Torres JM,Paz-Ares L,et al. Brain metastases from lung cancer responding to erlotinib:the importance of EGFR mutation[J].Eur Respir J,2011,37(3):624-631.DOI:10.1183/09031936.00195609. [28] Wu YL,Zhou C,Cheng Y,et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases:a phase Ⅱ study (CTONG-0803)[J].Ann Oncol,2013,24(4):993-999.DOI:10.1093/annonc/mds529. [29] Fan Y,Xu XL,Xie CH.EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer:a pooled analysis of published data[J].Onco Targets Ther,2014,7:2075-2084.DOI:10.2147/OTT.S67586. [30] Li HW,Zhang XQ,Cao JZ,et al. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer[J].Tumour Biol,2015.DOI:10.1007/s13277-015-3653-2. [31] Omuro AMP,Kris MG,Miller VA,et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib[J].Cancer,2005,103(11):2344-2348.DOI:10.1002/cncr.21033. [32] Park SJ,Kim HT,Lee DH,et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation[J].Lung Cancer,2012,77(3):556-560.DOI:10.1016/j.lungcan.2012.05.092. [33] Bianco C,Tortora G,Bianco R,et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839(Iressa)[J].Clin Cancer Res,2002,8(10):3250-3258. [34] Chinnaiyan P,Huang S,Vallabhaneni G,et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)[J].Cancer Res,2005,65(8):3328-3335.DOI:10.1158/0008-5472.CAN-04-3547. [35] Zeng YD,Zhang L,Liao H,et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer:a retrospective study[J].Asian Pac J Cancer Prev,2012,13(3):909-914.DOI:10.7314/APJCP.2012.13.3.909. [36] Cai L,Zhu JF,Zhang XW,et al. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer[J].J Neuro Oncol,2014,120(2):423-430.DOI:10.1007/s11060-014-1570-7. [37] Welsh JW,Komaki R,Amini A,et al. Phase Ⅱ trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer[J].J Clin Oncol,2013,31(7):895-902.DOI:10.1200/JCO.2011.40.1174. [38] Sperduto PW,Wang M,Robins HI,et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases:Radiation Therapy Oncology Group 0320[J].Int J Radiat Oncol Biol Phys,2013,85(5):1312-1318.DOI:10.1016/j.ijrobp.2012.11.042.
2016, Vol. 25 
